{"id":531994,"date":"2021-02-26T20:32:01","date_gmt":"2021-02-26T20:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531994"},"modified":"2021-02-26T20:32:01","modified_gmt":"2021-02-26T20:32:01","slug":"progressive-familial-intrahepatic-cholestasis-market-insights-and-market-trend-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/progressive-familial-intrahepatic-cholestasis-market-insights-and-market-trend-by-delveinsight_531994.html","title":{"rendered":"Progressive Familial Intrahepatic Cholestasis: Market Insights and Market Trend by DelveInsight"},"content":{"rendered":"
\"Progressive<\/a><\/div>\n

DelveInsight has launched a new report on Progressive Familial Intrahepatic Cholestasis Market<\/strong><\/a><\/span><\/p>\n

 <\/p>\n

Progressive Familial Intrahepatic Cholestasis<\/strong> is a disorder that causes progressive liver disease, which typically leads to liver failure in which liver cells are unable to secrete a digestive fluid called bile. The buildup of bile in liver cells causes liver disease in affected individuals. The average age at onset is three months, although some patients do not develop jaundice until later, even as late as adolescence. PFIC can progress rapidly and cause cirrhosis during infancy or may progress relatively slowly with minimal scarring into adolescence. Few patients survive into the third decade of life without treatment.<\/p>\n

 <\/p>\n

The key players elaborated in the Progressive Familial Intrahepatic Cholestasis Market report includes <\/strong>Mirum Pharmaceuticals, Albiro etc<\/p>\n

 <\/strong><\/p>\n

Download Free Report Sample-<\/strong> https:\/\/www.delveinsight.com\/sample-request\/progressive-familial-intrahepatic-cholestasis-pfic-market <\/strong><\/a><\/span><\/p>\n

 <\/p>\n

There are mainly three types of PFIC which occur due to mutations in the genes, such as ATP8B1, ABCB11, and ABCB4, which result in development of PFIC1, PFIC2, and PFIC3 respectively. Mutations in these genes lead to a failure of proteins to function normally and thereby cause PFIC in many patients. PFIC usually appears in the first months of life in patients with PFIC1 resulting in characterized by recurrent episodes of jaundice, which become permanent later in the course of the disease. In case of PFIC2, the initial presentation and the evolution seem to become more severe, resulting into permanent jaundice from the first months of life and the rapid appearance of liver failure within the first years of life.<\/p>\n

 <\/strong><\/p>\n

Progressive Familial Intrahepatic Cholestasis Market<\/strong> Key Companies<\/strong><\/p>\n